Predictors, Barriers, and Facilitators of Lipid-Lowering Medication Use Among African Americans in a Primary Care Clinic

被引:3
|
作者
Schwartz, Kendra L. [1 ]
Dailey, Rhonda [1 ]
Bartoces, Monina [1 ]
Binienda, Juliann [1 ]
Archer, Carolyn [1 ]
Neale, Anne Victoria [1 ]
机构
[1] Wayne State Univ, Sch Med, Dept Family Med, Detroit, MI USA
关键词
cholesterol; statins; African Americans; NUTRITION EXAMINATION SURVEY; CORONARY-HEART-DISEASE; PRIMARY HYPERCHOLESTEROLEMIA; CONTROLLED-TRIAL; NATIONAL-HEALTH; RISK-FACTORS; CHOLESTEROL; PREVALENCE; EFFICACY; METAANALYSIS;
D O I
10.1016/S0027-9684(15)31043-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Hypercholesterolemic African Americans are less likely than white Americans to be taking lipid-lowering medications, yet they suffer disproportionately from coronary heart disease (CHD). Methods: Through medical record abstraction and focus groups with patients and physicians, we sought a better understanding of the predictors, barriers, and facilitators to lipid-lowering medication use in a Detroit primary care clinic. Stepwise regression analysis included 634 African American patients with abnormal cholesterol values (n = 575) or currently prescribed a lipid-lowering medication (n = 59). Focus group transcripts were analyzed with a framework approach. Results: Overall 174 (30.3%) of hypercholesterolemic African Americans were prescribed a lipid-lowering medication. Patients with hypertension or CHID were significantly more likely to have a lipid-lowering medication prescription than those without, adjusted prevalence ratio 2.56 (95% Cl, 1.76-3.74) for hypertension and 1.70 (95% Cl, 1.45-2.00) for CHD. Focus groups revealed 2 barriers to lipid-lowering medication use named by both physicians (n = 12) and patients (n = 23): cost and forgetting to take medication, often because of lack of symptoms. Conclusions: Physicians and patients suggested better education by physicians and at the community level to improve lipid-lowering medication use. Simple and direct patient-physician discussions emphasizing long-term benefits are recommended.
引用
收藏
页码:944 / 952
页数:9
相关论文
共 50 条
  • [1] Proactive Pharmaceutical Care Interventions Improve Patients' Adherence to Lipid-Lowering Medication
    Stuurman-Bieze, Ada G. G.
    Hiddink, Eric G.
    van Boven, Job F. M.
    Vegter, Stefan
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (11) : 1448 - 1456
  • [2] Lipid disorders among Black Africans non-users o lipid-lowering medication
    Borgo, Mariana Veronez
    Baldo, Marcelo Perim
    Alvim, Rafael de Oliveira
    Zaniqueli, Divanei
    Capingana, Daniel Pires
    Magalhaes, Pedro
    da Silva, Amilcar Bernardo
    Oliosa, Polyana Romano
    Sartorio, Carmem Luiza
    Mill, Jose Geraldo
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2018, 62 (05): : 552 - 559
  • [3] Ineffectiveness of lipid-lowering therapy in primary care
    Van Ganse, E
    Souchet, T
    Laforest, L
    Moulin, P
    Bertrand, M
    Le Jeunne, P
    Travier, N
    Yin, D
    Alemao, E
    de Pouvourville, G
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (04) : 456 - 463
  • [4] Reduction of cardiovascular events with the use of lipid-lowering medication in patients with familial hypercholesterolemia or severe primary hypercholesterolemia: A systematic review
    Masson, Walter
    Corral, Pablo
    Barbagelata, Leandro
    Lavalle-Cobo, Augusto
    Nogueira, Juan P.
    Siniawski, Daniel
    Ray, Kausik K.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2022, 16 (05) : 562 - 573
  • [5] Barriers and facilitators of medication adherence in hypertensive African Americans: A qualitative study
    Ogedegbe, G
    Harrison, M
    Robbins, L
    Mancuso, CA
    Allegrante, JP
    ETHNICITY & DISEASE, 2004, 14 (01) : 3 - 12
  • [6] Explaining the 25-year decline of serum cholesterol by dietary changes and use of lipid-lowering medication in Finland
    Valsta, Liisa M.
    Tapanainen, Heli
    Sundvall, Jouko
    Laatikainen, Tiina
    Mannisto, Satu
    Pietinen, Pirjo
    Vartiainen, Erkki
    PUBLIC HEALTH NUTRITION, 2010, 13 (6A) : 932 - 938
  • [7] Prevalence and Coexistence of Cardiovascular Comorbidities Among the US Dyslipidemic Population Aged ≥ 65 Years by Lipid-Lowering Medication Use Status
    Candrilli, Sean D.
    Kuznik, Andreas
    Mendys, Philip M.
    Wilson, Daniel J.
    POSTGRADUATE MEDICINE, 2010, 122 (05) : 142 - 149
  • [8] Lipid-lowering therapy use and achievement of cholesterol targets in an Australian diabetes clinic
    Kiburg, Katerina V.
    Ward, Glenn M.
    O'Neal, David N.
    MacIsaac, Richard J.
    INTERNAL MEDICINE JOURNAL, 2018, 48 (02) : 201 - 204
  • [9] Adherence to lipid-lowering guidelines for secondary prevention and potential reduction in CVD events in Swedish primary care: a cross-sectional study
    Odesjo, Helena
    Bjorck, Staffan
    Franzen, Stefan
    Hjerpe, Per
    Manhem, Karin
    Rosengren, Annika
    Thorn, Jorgen
    Adamsson Eryd, Samuel
    BMJ OPEN, 2020, 10 (10):
  • [10] Medication Adherence and Treatment Satisfaction With Lipid-Lowering Drugs Among Patients With Diabetes and Dyslipidemia
    Alfadda, Assim A.
    Youssef, Amira M.
    Al-Sofiani, Mohammed E.
    Amin, Hussein Saad
    AlOtaibi, Obeed
    Mohamed, Nourhan
    Algohani, Hossam Ayed
    Isnani, Arthur
    Rafiullah, Mohamed
    ANNALS OF PHARMACOTHERAPY, 2025, 59 (02) : 105 - 116